Lantheus Holdings, Inc. (LNTH)Healthcare | Drug Manufacturers - Specialty & Generic | Bedford, United States | NasdaqGM
100.02 USD
-0.09
(-0.090%) ⇩
(Oct. 13, 2026, 4 p.m.
EDT)
After hours: 100.02 |
Hot Take ↕ | Oct. 10, 2026, 9:21 a.m. EDT
Lantheus offers a solid long-term investment thesis driven by a fortress balance sheet and a return on equity exceeding 22 percent, even though revenue growth has slowed to 2.7 percent. The stock trades well above its 200-day moving average, indicating strong momentum, and analysts maintain a buy rating with a target price above the current level. However, there is no dividend income to support the total return. The options market shows mixed positioning, with traders purchasing deep out-of-the-money calls while simultaneously buying protective puts at lower strikes. While the statistical forecast model suggests a neutral bias for the near term, the fundamental quality supports a positive long-term view. |
| Model | MAE |
|---|---|
| AutoARIMA ✓ | 0.034702 |
| AutoETS | 0.035428 |
| MSTL | 0.035626 |
| AutoTheta | 0.067088 |
Forecast horizon: 45 days | Selected: AutoARIMA
| Forecast Reliability | |
|---|---|
| Score | 49% |
| H-stat | 1.43 |
| Ljung-Box p | 0.045 |
| Jarque-Bera p | 0.000 |
| Excess Kurtosis | 16.00 |
| Attribute | Value |
|---|---|
| Sector | Healthcare |
| Debt to Equity Ratio | 47.642 |
| Revenue per Share | 23.7 |
| Market Cap | 6,531,293,184 |
| Trailing P/E | 24.22 |
| Forward P/E | 15.68 |
| Beta | -0.06 |
| Profit Margins | 17.69% |
| Website | https://www.lantheus.com |
As of Oct. 10, 2026, 9:21 a.m. EDT: Speculators are positioning for a wide range of outcomes with notable open interest in deep out-of-the-money calls (120 strike in December 2026, 150 strike in January 2027) alongside significant protective put buying at the 45 strike level. This suggests a belief in potential upside while maintaining a hedge against a significant downside event. Implied volatility remains compressed for near-term expirations.
| Attribute | Value |
|---|---|
| 52 Week Change | 0.8178681 |
| Address1 | 201 Burlington Road |
| Address2 | South Building |
| All Time High | 126.89 |
| All Time Low | 1.76 |
| Ask | 129.74 |
| Ask Size | 2 |
| Audit Risk | 6 |
| Average Analyst Rating | 2.5 - Buy |
| Average Daily Volume10 Day | 876,500 |
| Average Daily Volume3 Month | 1,322,356 |
| Average Volume | 1,322,356 |
| Average Volume10Days | 876,500 |
| Beta | -0.058 |
| Bid | 72.62 |
| Bid Size | 2 |
| Board Risk | 4 |
| Book Value | 20.099 |
| City | Bedford |
| Compensation As Of Epoch Date | 1,767,139,200 |
| Compensation Risk | 2 |
| Country | United States |
| Crypto Tradeable | 0 |
| Currency | USD |
| Current Price | 100.02 |
| Current Ratio | 3.06 |
| Custom Price Alert Confidence | HIGH |
| Date Short Interest | 1,790,726,400 |
| Day High | 100.2775 |
| Day Low | 99.985 |
| Debt To Equity | 47.642 |
| Display Name | Lantheus |
| Dividend Yield | 0.0 |
| Earnings Call Timestamp End | 1,786,046,400 |
| Earnings Call Timestamp Start | 1,786,046,400 |
| Earnings Growth | -0.009 |
| Earnings Quarterly Growth | -0.047 |
| Earnings Timestamp | 1,786,019,400 |
| Earnings Timestamp End | 1,793,881,800 |
| Earnings Timestamp Start | 1,793,881,800 |
| Ebitda | 392,224,992 |
| Ebitda Margins | 0.25202 |
| Enterprise To Ebitda | 16.726 |
| Enterprise To Revenue | 4.215 |
| Enterprise Value | 6,560,202,240 |
| Eps Current Year | 5.35937 |
| Eps Forward | 6.37732 |
| Eps Trailing Twelve Months | 4.13 |
| Esg Populated | 0 |
| Exchange | NGM |
| Exchange Data Delayed By | 15 |
| Exchange Timezone Name | America/New_York |
| Exchange Timezone Short Name | EDT |
| Fax | 978 671 8860 |
| Fifty Day Average | 100.4762 |
| Fifty Day Average Change | -0.45619965 |
| Fifty Day Average Change Percent | -0.0045403754 |
| Fifty Two Week Change Percent | 81.78681 |
| Fifty Two Week High | 111.86 |
| Fifty Two Week High Change | -11.840004 |
| Fifty Two Week High Change Percent | -0.10584663 |
| Fifty Two Week Low | 50.155 |
| Fifty Two Week Low Change | 49.864998 |
| Fifty Two Week Low Change Percent | 0.99421793 |
| Fifty Two Week Range | 50.155 - 111.86 |
| Financial Currency | USD |
| First Trade Date Milliseconds | 1,435,239,000,000 |
| Float Shares | 58,613,282 |
| Forward Eps | 6.37732 |
| Forward P E | 15.683704 |
| Free Cashflow | 451,656,000 |
| Full Exchange Name | NasdaqGM |
| Full Time Employees | 1,193 |
| Fullday Change | -0.09000397 |
| Fullday Change Percent | -0.08990507 |
| Fullday Price | 100.02 |
| Gmt Off Set Milliseconds | -14,400,000 |
| Governance Epoch Date | 1,790,812,800 |
| Gross Margins | 0.60143 |
| Gross Profits | 936,017,984 |
| Has Pre Post Market Data | 1 |
| Held Percent Insiders | 0.01731 |
| Held Percent Institutions | 1.17002 |
| Implied Shares Outstanding | 65,299,875 |
| Industry | Drug Manufacturers - Specialty & Generic |
| Industry Disp | Drug Manufacturers - Specialty & Generic |
| Industry Key | drug-manufacturers-specialty-generic |
| Is Earnings Date Estimate | 0 |
| Language | en-US |
| Last Fiscal Year End | 1,767,139,200 |
| Long Business Summary | Lantheus Holdings, Inc. develops, manufactures, and commercializes diagnostic and therapeutic products that assist clinicians in diagnosis and treatment of heart, cancer, and other diseases worldwide. The company offers DEFINITY, an injectable ultrasound enhancing agent used in echocardiography exams; TechneLite, a technetium generator for nuclear medicine procedures; Xenon-133, a radiopharmaceutical gas to assess pulmonary function; Neurolite, an injectable imaging agent to identify the area within the brain where blood flow has been blocked or reduced due to stroke; Cardiolite, an injectable Tc-99m-labeled imaging agent to assess blood flow to the muscle of the heart; and PYLARIFY, an F 18-labelled PSMA-targeted PET imaging agent used for imaging of PSMA positive-lesions in men with prostate cancer. It also provides Automated Bone Scan Index that calculates the disease burden of prostate cancer by detecting and classifying bone scan tracer uptakes as metastatic or benign lesions using an artificial neural network; RELISTOR for opioid-induced constipation; and aPROMISE, an artificial intelligence medical device software; PYLARIFY AI, an medical device software to perform quantitative assessment of PSMA PET/CT images in prostate cancer; and flurpiridaz used to assess blood flow to the heart. In addition, it develops PNT2002, a radiopharmaceutical therapy to treat mCRPC; PNT2003, an SSTR therapy to patients with SSTR-positive neuroendocrine tumors; MK-6240, a F 18-labeled PET imaging agent for Tau tangles in Alzheimer's disease; LNTH-2401, a novel radiodiagnostic targeting the gastrin-releasing peptide receptor; LNTH-2402; LNTH-2403; LNTH-2404; LNTH-250; LNTH-2515; and LNTH-1363S, an fibroblast activation protein, alpha, copper-64 labeled PET imaging agent. It has collaboration agreements with GE Healthcare; Curium Pharma; POINT; Regeneron; and Ratio Therapeutics LLC. The company was founded in 1956 and is based in Bedford, Massachusetts. |
| Long Name | Lantheus Holdings, Inc. |
| Market | us_market |
| Market Cap | 6,531,293,184 |
| Market State | POST |
| Max Age | 86,400 |
| Message Board Id | finmb_8285048 |
| Most Recent Quarter | 1,782,777,600 |
| Net Income To Common | 275,304,992 |
| Next Fiscal Year End | 1,798,675,200 |
| Non Diluted Market Cap | 6,529,334,501 |
| Number Of Analyst Opinions | 8 |
| Open | 100.18 |
| Operating Cashflow | 412,801,984 |
| Operating Margins | 0.25817 |
| Overall Risk | 2 |
| Payout Ratio | 0.0 |
| Phone | 978 671 8001 |
| Post Market Change | 0.0 |
| Post Market Change Percent | 0.0 |
| Post Market Price | 100.02 |
| Post Market Time | 1,791,926,892 |
| Previous Close | 100.11 |
| Price Eps Current Year | 18.66264 |
| Price Hint | 2 |
| Price To Book | 4.9763665 |
| Price To Sales Trailing12 Months | 4.1966453 |
| Profit Margins | 0.1769 |
| Quick Ratio | 2.822 |
| Quote Source Name | Nasdaq Real Time Price |
| Quote Type | EQUITY |
| Recommendation Key | buy |
| Recommendation Mean | 2.5 |
| Region | US |
| Regular Market Change | -0.09000397 |
| Regular Market Change Percent | -0.089905076 |
| Regular Market Day High | 100.2775 |
| Regular Market Day Low | 99.985 |
| Regular Market Day Range | 99.985 - 100.2775 |
| Regular Market Open | 100.18 |
| Regular Market Previous Close | 100.11 |
| Regular Market Price | 100.02 |
| Regular Market Time | 1,791,921,601 |
| Regular Market Volume | 1,531,494 |
| Return On Assets | 0.08379 |
| Return On Equity | 0.22215 |
| Revenue Growth | 0.027 |
| Revenue Per Share | 23.7 |
| Sand P52 Week Change | 0.17502642 |
| Sector | Healthcare |
| Sector Disp | Healthcare |
| Sector Key | healthcare |
| Share Holder Rights Risk | 2 |
| Shares Outstanding | 65,299,875 |
| Shares Percent Shares Out | 0.0579 |
| Shares Short | 3,783,610 |
| Shares Short Previous Month Date | 1,788,134,400 |
| Shares Short Prior Month | 4,236,654 |
| Short Name | Lantheus Holdings, Inc. |
| Short Percent Of Float | 0.0678 |
| Short Ratio | 3.67 |
| Source Interval | 15 |
| State | MA |
| Symbol | LNTH |
| Target High Price | 115.0 |
| Target Low Price | 102.5 |
| Target Mean Price | 106.9875 |
| Target Median Price | 105.2 |
| Total Cash | 593,297,984 |
| Total Cash Per Share | 9.09 |
| Total Debt | 624,958,016 |
| Total Revenue | 1,556,312,960 |
| Tradeable | 0 |
| Trailing Annual Dividend Rate | 0.0 |
| Trailing Annual Dividend Yield | 0.0 |
| Trailing Eps | 4.13 |
| Trailing P E | 24.217916 |
| Trailing Peg Ratio | None |
| Triggerable | 1 |
| Two Hundred Day Average | 89.0959 |
| Two Hundred Day Average Change | 10.924095 |
| Two Hundred Day Average Change Percent | 0.122610524 |
| Type Disp | Equity |
| Volume | 1,531,494 |
| Website | https://www.lantheus.com |
| Zip | 1,730 |